

Recently Available and Emerging Systemic Treatments for Prostate Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In the Phase III ALSYMPCA study for patients with castration-resistant prostate cancer and bone metastases, treatment with radium-223 chloride resulted in an improvement in overall survival.  
a. True  
b. False
2. MDV3100 is a(n) \_\_\_\_\_.  
a. Third-generation taxane  
b. Immunotherapeutic agent  
c. Antiandrogen with a high affinity for the androgen receptor
3. Abiraterone inhibits CYP17 and decreases testosterone in patients with prostate cancer.  
a. True  
b. False
4. The Phase III TROPIC trial is comparing the novel taxane cabazitaxel in combination with prednisone to \_\_\_\_\_ for patients with metastatic castration-resistant prostate cancer.  
a. Docetaxel/prednisone  
b. Mitoxantrone/prednisone  
c. Placebo/prednisone
5. Which of the following is the mechanism of action of the novel agent TAK-700 (orteronel)?  
a. HER2 inhibition  
b. GnRH modulation  
c. Sex hormone synthesis inhibition
6. The Phase III IMPACT trial for patients with metastatic prostate cancer compares \_\_\_\_\_ to the control arm.  
a. Abiraterone/prednisone  
b. Radium-223 chloride  
c. Sipuleucel-T
7. In the COU-AA-301 study, abiraterone acetate prolonged overall survival compared to placebo for patients with metastatic castration-resistant prostate cancer who had experienced disease progression on previous docetaxel therapy.  
a. True  
b. False
8. The Phase III FIRSTANA trial for patients with metastatic castration-resistant prostate cancer will randomly assign patients to 2 different doses of \_\_\_\_\_ or docetaxel.  
a. Cabozantinib  
b. Abiraterone  
c. MDV3100  
d. Cabazitaxel
9. Which of the following agents has been shown to decrease skeletal-related events in patients with metastatic castration-resistant prostate cancer?  
a. Zoledronic acid  
b. Denosumab  
c. Both a and b  
d. None of the above
10. Which of the following agents has a similar mechanism of action to that of abiraterone?  
a. Bicalutamide  
b. MDV3100  
c. TAK-700